Personalized Predictive Care. Anywhere.

Powered by artificial intelligence and machine learning, Biofourmis enables the delivery of care to patients in nearly any location, providing unique insights into each patient’s condition.

man and woman reading brochure

Biofourmis Care™

Personalize care virtually anywhere, with customized solutions to help clinicians provide care to patients with acute, post-acute, and chronic conditions.

Biofourmis Therapeutics™

Biofourmis is advancing drug development, clinical research, and Software as a Medical Device (SaMD) through the use of the latest artificial intelligence and machine learning technology across a spectrum of therapeutic areas.

Product Lineup home screen

Intelligent care, anywhere, begins with Biofourmis

bottom white curve

One Partner for Your Virtual Care Needs

Our customized, end-to-end solutions with our FDA-cleared analytics platform enable world-class care to patients and advanced insight to clinicians.

Continuous, Real-Time Monitoring

Patient App Designed to Optimize Engagement and Adherence

Graphic

FDA-cleared Analytics Platform

Actionable Notifications for Clinicians

Enterprise-level Scale and Integration

One Partner for Your Virtual Care Needs

Our customized, end-to-end solutions with our FDA-cleared analytics platform enable world-class care to patients and advanced insight to clinicians.

one partner
dots

Continuous, Real-time Monitoring

Patient App Designed to Optimize Engagement and Adherence

FDA-cleared Analytics Platform

Actionable Notification for Clinicians

Enterprise-level Scale and Integration

top blue curve
BI index with vitals in device

Welcome to the Next Level of Care

Delivery of care from anywhere, powered by the Biovitals analytics engine. The Biovitals FDA-cleared software utilizes AI and machine-learning to deliver meaningful notifications and unique insights to care teams.

pre footer wave

Utilizing Clinical Evidence and Science as our Guide

Around the world and across multiple collaborations and studies, Biofourmis is helping clinical teams see patients like never before.

BioVitalsHF Treatment Algorithms
Circulation, AHA Journal

This RCT demonstrated that an algorithm-driven, navigator-administered medication optimized program enhanced implementation of GDMT compared with usual care in patients with HFrEF. The data supports remote titration using our Biovitals Treatment algorithms for personalized, sequential, stepped titration of guideline-directed heart failure medication therapies.
American Heart Association Logo

Remote Monitoring with Biosensors and AI
Annals of Internal Medicine

This RCT demonstrated substitutive hospital-level care in a patient’s home may reduce cost, health care use and readmissions, while improving the patient experience. Patients were monitored using a wearable biosensor patch and machine-based algorithms, which produced alarms for review by nurses and physicians.
aim logo

BioVitals  A Personalized Physiology Analytics
IEEE Explore

This study demonstrated the ability of our FDA-cleared BioVitals Analytics Engine to detect subtle physiology changes precursor to decompensation in patients with chronic conditions. The data validates the use of our device- and disease-agnostic platform for continuous physiology monitoring.
Ieeexplore logo

RhythmAnalytics – Deep Learning for Arrhythmia Detection arXive.org – Cornell University

This study demonstrated the capability of our FDA-cleared RhythmAnalytics platform to detect >15 types of cardiac arrhythmias using continuous ECG recordings. The overall performance of RhythmAnalytics outperformed a panel of cardiologists and other industry-leading detection models.

Cornell University Logo

Awards

Since its founding in 2015, digital therapeutics and remote monitoring startup Biofourmis has been trying to figure out how to move healthcare beyond the pill.
Forbes partnered with venture firms Sequoia Capital and Meritech Capital to create our second annual AI 50, a list of private, U.S.-based companies that are using artificial intelligence in meaningful business-oriented ways.
In 2019, digital health companies from 18 countries spanning 17 overarching categories were selected for the first-ever annual CB Insights Digital Health 150.
Biofourmis had to present their innovation and demonstrate how virtual care and digital therapeutics can disrupt clinical trials to an esteemed panel of judges, followed by a rigorous Q&A.

Trusted by Leading Health Systems, Providers, Pharmaceutical Companies, and More

novartis logo
massachusetts general hospital logo
bringham and womens hospital logo
astrazeneca logo
mayo clinic logo
chugai logo
mundipharma logo
singhealth logo
cersi logo
nsw logo
nhs logo
university of hong kong logo
wave

Biofourmis in The News

Let’s get you up to speed.
wave

What Our Customers Are Saying

Start Delivering Powerful, Predictive, Virtual Care Today